Blood test predicts success of neuroendocrine cancer therapy
Monday, June 13, 2016 - 11:01
in Health & Medicine
Malignant neuroendocrine tumors are relatively rare, notoriously difficult to treat, and associated with poor long-term survival. An investigative blood test could predict how patients will respond to peptide receptor radionuclide therapy before they commit to a course of treatment.